Atezolizumab plus a modified docetaxel, cisplatin and 5-fluorouracilregimen is a safe and effective first-line treatment for locally advanced squamous cell anal carcinoma, according to research presented at 2022 ASCO Annual Meeting.Anal carcinomas make up 2.7% of gastrointestinal cancers, which has increased over time, according to the study's authors.